International Stem Cell Corporation Reports Q3 2025 Financial Results with Increased Sales and Reduced Net Losses

International Stem Cell Corporation (ISCO) reported its financial results for the third quarter and the first nine months of 2025, revealing a modest increase in product sales and a reduction in net losses compared to the same period in 2024. For the three months ended September 30, 2025, ISCO generated $2.37 million in product sales, a 9% increase from $2.18 million in the prior year. For the nine-month period, total product sales reached $6.95 million, up 5% from $6.64 million in 2024. The company reported a net income of $57,000 for the third quarter, a significant improvement from a net loss of $125,000 in the same quarter last year. For the nine months, the net loss narrowed to $70,000 from $220,000 in 2024.

The company's operating expenses for the third quarter were $2.28 million, slightly higher than the $2.27 million reported in the same quarter of 2024. The increase was primarily driven by a rise in research and development costs, which totaled $158,000, down from $187,000 a year earlier. General and administrative expenses decreased by 3% to $789,000, while selling and marketing expenses also saw a slight decline. The overall profit margin for the third quarter improved to 56%, compared to 55% in the previous year, reflecting better performance in the biomedical segment.

In terms of operational developments, ISCO's biomedical market segment, which includes Lifeline Cell Technology, contributed significantly to the sales increase, particularly in cell and media products. The company reported a notable increase in sales from its biomedical products, which totaled $2.20 million for the quarter, compared to $2.00 million in the prior year. However, sales from the anti-aging skin care segment, Lifeline Skin Care, decreased to $165,000 from $179,000 in the same quarter of 2024. The company continues to focus on its therapeutic market, particularly in developing treatments for Parkinson's disease, traumatic brain injury, and stroke.

As of September 30, 2025, ISCO's total assets amounted to $5.28 million, a slight increase from $5.17 million at the end of 2024. The company reported an accumulated deficit of approximately $110.8 million, raising concerns about its ability to sustain operations without additional financing. The company had cash reserves of $966,000, down from $1.23 million at the end of 2024. ISCO is actively exploring various financing options to support its ongoing research and development efforts and maintain its operational capabilities.

Looking ahead, ISCO's management expressed the need for significant additional capital to fund its operations and product development initiatives. The company is evaluating potential financing sources, including equity and debt financing, grants, and collaborative research arrangements. The management's ability to secure funding will be critical for the company's future, as it continues to navigate the challenges of maintaining cash flow and advancing its therapeutic product candidates.